Jasper Therapeutics’ c-Kit inhibitor, briquilimab, demonstrated efficacy in a Phase II trial in patients with chronic spontaneous urticaria (CSU) that appears on par with rival Celldex’s barzolvolimab. However, the small data set and some questions about dosing may have spooked investors, with the company’s stock opening down 50% at $8.74 on 8 January then dropping further to close the day at $6.99, despite the generally positive results.
Jasper’s Briquilimab Stands Up To Competition, But Investors Bail
The company reported positive Phase II data from the BEACON trial testing the c-Kit inhibitor in chronic spontaneous urticaria and said it is planning a Phase IIb/III program.
